The 13th International AIDS Society Conference on HIV Science (IAS 2025)

In children living with HIV initiating antiretroviral therapy (ART), factors such as the ART regimen, age, BMI, and baseline CD4 count, among others, can predict treatment failure, according to a study.

A once-weekly oral antiretroviral therapy (ART) regimen combining the nucleoside reverse transcriptase translocation inhibitor (NRTTI) islatravir with the non-nucleoside reverse transcriptase inhibitor (NNRTI) ulonivirine helps maintain viral suppression in adults living with HIV-1, according to a phase IIb study.

A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts from the GS-US-216-0128 study presented at IAS 2025.

Switching to maintenance dual antiretroviral therapy (ART) with DTG+3TC* or ATV/r+3TC** was noninferior to continuing triple current ART with TDF+3TC+EFV*** or DTG+3TC+TDF⁺ in maintaining virologic suppression for up to 96 weeks among people living with HIV (PLWH), according to the MODERATO trial presented at IAS 2025.